Log in

Trevi Therapeutics Stock Forecast, Price & News

-0.13 (-3.32 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $3.79
50-Day Range
MA: $4.32
52-Week Range
Now: $3.79
Volume14,950 shs
Average Volume83,505 shs
Market Capitalization$69.13 million
P/E RatioN/A
Dividend YieldN/A
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TRVI



Sales & Book Value

Annual SalesN/A
Book Value$3.06 per share


Net Income$-26,050,000.00


Market Cap$69.13 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
-0.13 (-3.32 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

How has Trevi Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRVI shares have increased by 19.2% and is now trading at $3.79.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Trevi Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Trevi Therapeutics

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Trevi Therapeutics

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics Inc (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.10.
View Trevi Therapeutics' earnings history

What price target have analysts set for TRVI?

4 analysts have issued 12-month price objectives for Trevi Therapeutics' shares. Their forecasts range from $9.00 to $13.00. On average, they expect Trevi Therapeutics' stock price to reach $11.00 in the next year. This suggests a possible upside of 190.2% from the stock's current price.
View analysts' price targets for Trevi Therapeutics

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 27,500 shares, a decrease of 67.1% from the August 15th total of 83,700 shares. Based on an average daily trading volume, of 110,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.0% of the company's stock are sold short.
View Trevi Therapeutics' Short Interest

Who are some of Trevi Therapeutics' key competitors?

What other stocks do shareholders of Trevi Therapeutics own?

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:
  • Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)
  • Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)
  • Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)
  • Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)
  • Dr. Amale Hawi, Sr. VP of CMC (Age 65)

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include NEA Management Company LLC (33.29%), TPG Group Holdings SBS Advisors Inc. (27.04%), Omega Fund Management LLC (7.71%), Bridgeway Capital Management Inc. (0.55%) and Canada Pension Plan Investment Board (0.22%). Company insiders that own Trevi Therapeutics stock include Anne Vanlent, Enterprise Associates 16 New, Invest A/S Lundbeckfond and Jennifer L Good.
View institutional ownership trends for Trevi Therapeutics

Which institutional investors are selling Trevi Therapeutics stock?

TRVI stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc..
View insider buying and selling activity for Trevi Therapeutics

Which institutional investors are buying Trevi Therapeutics stock?

TRVI stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Omega Fund Management LLC, Canada Pension Plan Investment Board, and Bridgeway Capital Management Inc.. Company insiders that have bought Trevi Therapeutics stock in the last two years include Anne Vanlent, Invest A/S Lundbeckfond, and Jennifer L Good.
View insider buying and selling activity for Trevi Therapeutics

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $3.79.

How big of a company is Trevi Therapeutics?

Trevi Therapeutics has a market capitalization of $69.13 million. The company earns $-26,050,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Trevi Therapeutics employs 15 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.